GUTS · Fractyl Health, Inc.
$0.68
+0.02 (+2.72%)
At close · Aug 14
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, these existing cash resources are not expected to be sufficient to fund the Company's current operating plan for at least twelve months from the issuance date of this Quarterly Report on Form 10-Q. As a result, substantial doubt exists about the Company's ability to continue as a going concern for at least one year after the date that these financial statements are issued.”View the 10-Q filed Aug 10, 2026
Market Cap
$108.24M
Shares
159.18M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Harith Rajagopalan | M.D., Ph.D. Chief Executive Officer | $6,414,290 |
| Jay D. Caplan | President and Chief Product Officer | $3,043,034 |
| Sarah Toomey | General Counsel and Corporate Secretary | $2,445,850 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Harith Rajagopalan | M.D., Ph.D. Chief Executive Officer | $4,856,361 |
| Jay D. Caplan | President and Chief Product Officer | $2,198,612 |
| Lisa Davidson | Chief Financial Officer and Treasurer | $1,972,272 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Harith Rajagopalan | M.D., Ph.D. Chief Executive Officer | $3,561,774 |
| Jay D. Caplan | President and Chief Product Officer | $2,873,373 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Lisa Davidson | Chief Financial Officer | Resigned | 2026-01-06 |
| Lara Smith Weber | Chief Financial Officer | Appointed | 2026-01-06 |
| Amy W. Schulman | Class I director | Resigned | 2025-09-03 |
| Ian Sheffield | Class II director | Appointed | 2025-09-03 |
| Christopher Thompson, M.D. | Class I director | Appointed | 2025-09-03 |
Key facts
CIK
1572616
CUSIP
35168W103
13F (30d)
73 filings
73 filers
Visit website
Investor relations